

Annual Report and Audited Financial Statements for the year ended 30 June 2024

Caleo Global Flexible Fund IC Limited	
Annual Report and Audited Financial Statements for the year ended 30 June 2024 Contents	Page
General Information	3
Investment Manager's Report	4
Directors' Report	6
Independent Auditor's Report	8
Custodian's Report	11
Supplementary Information	12
Portfolio Statement	13
Statement of Financial Position	14
Statement of Comprehensive Income	15
Statement of Cash Flows	16
Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares	17
Notes to the Financial Statements	18

m

# Caleo Global Flexible Fund IC Limited Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### **General Information**

#### Address and Registered Office

PO Box 255 Trafalgar Court, Les Banques St Peter Port, Guernsey GY1 3QL Channel Islands

#### **Investment Manager**

Momentum Global Investment Management Limited The Rex Building 62 Queen Street London EC4R 1EB United Kingdom

#### Sub-Investment Manager and Distribution Partner

Caleo Capital (Pty) Ltd Atlantic House Glenhove Square 71 4th Street, Houghton 2198 South Africa

#### Manager

Momentum Wealth International Limited La Plaiderie House La Plaiderie St Peter Port, Guernsey GY1 1WF Channel Islands

## **Custodian** Northern Trust (Guernsey) Limited PO Box 71 Trafalgar Court Les Banques St Peter Port, Guernsey GY1 3DA Channel Islands

# Directors of the Incorporated Cell Robert Alastair Rhodes Roxanne Power

Marie Curutchet Ray Mhere Andrew Hardy (appointed 15 December 2023) Ferdinand van Heerden (resigned 1 December 2023)

#### Administrator, Registrar & Secretary

Northern Trust International Fund Administration Services (Guernsey) Limited PO Box 255 Trafalgar Court Les Banques St Peter Port, Guernsey GY1 3QL Channel Islands

#### Legal Advisors

Carey Olsen Carey House Les Banques St Peter Port, Guernsey GY1 4BZ Channel Islands

#### **Independent Auditor**

Ernst & Young LLP PO Box 9 Royal Chambers St Julian's Avenue St Peter Port, Guernsey GY1 4AF Channel Islands



#### Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### **Investment Manager's Report**

The Caleo Global Flexible Fund is a global flexible fund that provides investors with a significant participation in equity markets, however, allows the manager to scale down to moderate or even lower equity market exposures when deemed fit. This Fund will use asset allocation on a tactical basis to take advantage of valuation opportunities in the markets. This has particularly been the case over recent periods where markets have seen increased volatility.

#### Full year performance

2024 began on a positive note following an impressive rally in the final quarter of 2023, supportive of the funds performance as it produced returns that were in line with expectations on the back of strong corporate earnings, the market pricing in six interest rate cuts by the Federal Reserve (the "Fed") and data suggesting a soft landing for the US economy. Growth stocks continue to be the key drive behind performance as the Artificial Intelligence frenzy continued through the period, with magnificent 7 contributing most of the gains.

#### Performance measured against benchmark

Over the period in question, 1 July 2023 to 30 June 2024 the cell has managed to continue on a positive trajectory with market conditions setting the tone as global equities posted multiple consecutive months of positive performances. The cell registered returns in line with its market peers, with the fund returning 8.88% net of all fees compared to a benchmark return of 8.95% on the EAA USD Flexible Allocation as per Morningstar. A slight underperformance to the benchmark but overall, we remain confident regarding the current strategy in place.

#### Significant trends impacting performance

Inflation continued to be a central concern for markets. Despite signs of declining inflationary pressures, unexpected high inflation readings tempered enthusiasm for imminent rate cuts. Initially, the market expected faster central bank action to decrease interest rates. However, these anticipations were scaled back and government bonds adjusted to shifting market sentiments and economic data as bond yields increased across the board and bond prices came under pressure. We anticipate central banks to begin cutting rates before the end of the year, presenting a normalising policy from restrictive levels as the outlook for fixed income becomes positive.

On the equities front, global stocks seemed to continue their upward trend from the final quarter of 2023 on the back of strong gains buoyed by expectations that interest rates cuts were approaching as data reinforced market expectations that the Fed had come to the end of its rate hiking cycle and will shift towards cuts in 2024. Other notable key drivers continued to be a resilient US economy and enthusiasm around Artificial Intelligence as the magnificent 7 stocks contributed most of the gains during this period. The markets concentration of returns is increasingly under scrutiny as 60% of the S&P 500's returns can be attributed to just three companies, with the magnificent 7 stocks now accounting for 32% of the index. The magnificent 7 and many US stocks present strong margins and impressive returns on equity. However, while these structural factors are unlikely to change any time soon, our outlook is that there are several factors that are likely to cause stock market returns to broaden out going forward and less dependent on just a handful of names. We are well positioned for this rotation whilst tactically still retaining exposure to names that have done well this year.

We continue to hold a bias towards US rather than Europe in terms of developed market exposure but remain well positioned in terms of underlying managers to take advantage of the opportunities being offered by European markets as the economy emerges out of stagnation, supported by increasing external demand. With inflation receding further, the ECB will likely continue to cut rates in September 2024. The positive macroeconomic trends and earnings growth will be key drivers for positive performance for equities. We remain confident with the funds asset allocation and believe the current market environment will continue presenting opportunities for positive returns.

# Annual Report and Audited Financial Statements for the year ended 30 June 2024

Investment Manager's Report (continued)

#### Risks

During US election years, equity volatility tends to increase around mid-year as markets try to gauge not only Kamala Harris's chances against Donald Trump, but also whether a Harris presidency would mean a continuation of Bidens economic policies.

Tensions between Israel and Iran continue to escalate, applying further pressure to oil prices. In the case of a strong economy like the US, high oil prices can trigger cost shocks which generate increased wage demand and prolonged inflationary pressures. In this scenario, interest rates are likely to be kept at restrictive levels to limit further price rises. However, major escalations and excessive increases in oil prices are unlikely as regional players have an interest in keeping the conflict contained.

### Outlook for 2025

We continue to hold our equity exposure at neutral levels whilst keeping a sharp eye on the development of the risks stated above. We believe global economies to be in good shape but would not overlook the potential of a near term market correction. The balanced nature of the fund with the inclusion of both bond and cash holdings should help navigate these uncertainties with the ability to smooth any potential volatility. We believe the overall long-term health of the global economy to be good and would thus use any near-term corrections to build further equity positions. This would more than likely see equity levels increase from neutral to overweight.



#### Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### **Directors' Report**

The Directors present their annual report together with the audited financial statements of Caleo Global Flexible Fund IC Limited (the "Incorporated Cell" or "Cell") for the year ended 30 June 2024.

#### **Principal activities**

The Cell with company number 56161 is a Guernsey registered, Limited Liability Incorporated Cell of Momentum Mutual Fund ICC Limited (the "Company"). The activities and objectives of the Cell can be found in note 1 on page 18.

#### Going concern

The Directors have made an assessment of going concern including consideration of geo-political issues on the Cell. Refer to note 2 for the detailed disclosure.

#### Directors

The Directors of the Cell during the year and at the date of this report are set out on page 3.

#### Directors' interests

None of the Directors who held office during the year and at the date of this report had any disclosable interests in the shares of the Incorporated Cell.

#### **Directors' responsibilities**

The Directors are responsible for preparing the financial statements for each financial year, which give a true and fair view, in accordance with applicable Guernsey law and International Financial Reporting Standards, of the state of affairs of the Incorporated Cell and of the profit or loss of the Incorporated Cell for that period. In preparing these financial statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis, unless it is inappropriate to presume that the Incorporated Cell will continue in business.

The Directors confirm that they have complied with the above requirements in preparing the financial statements.

The Directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Incorporated Cell and enable them to ensure that the financial statements comply with The Companies (Guernsey) Law, 2008 and The Protection of Investors (Bailiwick of Guernsey) Law, 2020. They are also responsible for safeguarding the assets of the Incorporated Cell and hence, for taking reasonable steps for the prevention and detection of fraud and other irregularities.

So far as each Director is aware, there is no relevant audit information of which the Incorporated Cell's auditor is unaware and each Director has taken all the steps they ought to have as a Director to make themselves aware of any relevant audit information and to establish that the Incorporated Cell's auditor is aware of that information.

The Board of Directors confirms that, throughout the period covered by the financial statements, the Cell has complied with the Code of Corporate Governance issued by the Guernsey Financial Services Commission, to the extent it was applicable based upon its legal and operating structure and its nature, scale and complexity.



### Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### **Directors' Report (continued)**

#### **Directors' responsibilities (continued)**

The annual report together with the audited financial statements of the Incorporated Cell is published on the Manager's website. The Manager is responsible for the maintenance and integrity of the website; the work carried out by the auditor does not involve consideration of these matters and, accordingly, the auditor accepts no responsibility for any changes that may occur to the financial statements after they are initially presented on the website. The Directors appreciate there is uncertainty regarding legal requirements of information published on the internet as it is accessible in many countries and legislation in Guernsey governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

#### **Independent auditor**

A rule was issued by the Independent Regulatory Auditors in South Africa (IRBA), which prescribed mandatory audit firm rotation. The Board of Momentum Group Limited ("MGL"), formerly Momentum Metropolitan Holdings Limited approved the appointment of a joint external auditor for the 2025 financial year. Shareholders of MGL will be informed of the new firm of external auditors once all regulatory approvals have been obtained. The change of external audit firm will be tabled for approval by the shareholders at the MGL's next annual general meeting.

As a subsidiary of MGL, the Directors of the Cell anticipate that Ernst & Young LLP will tender their resignation and the Directors will seek to appoint a new audit firm in line with the wider group.

h

Marie Curutchet Director 2 October 2024

Robert Rhodes Director



### Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### Independent Auditor's Report to the Members of Caleo Global Flexible Fund IC Limited

#### Opinion

We have audited the financial statements of Caleo Global Flexible Fund IC Limited (the "Incorporated Cell") for the year ended 30 June 2024 which comprise the Statement of Financial Position, the Statement of Comprehensive Income, the Statement of Cash Flows, the Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares, and the related notes 1 to 16, including material accounting policy information. The financial reporting framework that has been applied in their preparation is applicable law and International Financial Reporting Standards.

In our opinion, the financial statements:

- give a true and fair view of the state of the Incorporated Cell's affairs as at 30 June 2024 and of its profit for the year then ended;
- have been properly prepared in accordance with International Financial Reporting Standards; and
- have been properly prepared in accordance with the requirements of The Companies (Guernsey) Law, 2008 and The Protection of Investors (Bailiwick of Guernsey) Law, 2020.

#### Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Incorporated Cell in accordance with the ethical requirements that are relevant to our audit of the financial statements, including the UK FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Incorporated Cell's ability to continue as a going concern for the period to 31 December 2025.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report. However, because not all future events or conditions can be predicted, this statement is not a guarantee as to the Incorporated Cell's ability to continue as a going concern.

#### Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in this report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statement we have performed, we conclude that there is a material misstatement of the other information, we are required to report that fact.

We have nothing to report in this regard.

### Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### Independent Auditor's Report to the Members of Caleo Global Flexible Fund IC Limited (continued)

#### Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which The Companies (Guernsey) Law, 2008 requires us to report to you if, in our opinion:

- proper accounting records have not been kept by the Incorporated Cell; or
- the financial statements are not in agreement with the Incorporated Cell's accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

#### **Responsibilities of directors**

As explained more fully in the directors' responsibilities statement set out on page 6, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the Incorporated Cell's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Incorporated Cell or to cease operations, or have no realistic alternative but to do so.

#### Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

#### Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect irregularities, including fraud. The risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below. However, the primary responsibility for the prevention and detection of fraud rests with both those charged with governance of the entity and management.

We obtained an understanding of the legal and regulatory frameworks that are applicable to the Incorporated Cell and determined that the most significant are those that relate to the reporting framework (International Financial Reporting Standards, The Companies (Guernsey) Law, 2008 and the Protection of Investors (Bailiwick of Guernsey) Law, 2020);

We understood how the Incorporated Cell is complying with those frameworks by making enquiries of management and those responsible for compliance matters and corroborated this by reviewing minutes of meetings of the Board of Directors and correspondence between the Incorporated Cell and the Guernsey Financial Services Commission. We gained an understanding of the Board's approach to governance, demonstrated by its review of compliance reports, the investment manager's reports and internal control processes;

### Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### Independent Auditor's Report to the Members of Caleo Global Flexible Fund IC Limited (continued)

# Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud (continued)

- We assessed the susceptibility of the Incorporated Cell's financial statements to material misstatement, including how fraud might occur by considering the risk of management override and by identifying the valuation of investments (specifically manual price overrides) and the recognition of dividend income at yearend (cut-off) as fraud risks. We considered the controls the Incorporated Cell has established to address the risk identified by the directors or that otherwise seek to prevent, detect or deter fraud and how management and those charged with governance monitor those controls. We also considered the existence of any stakeholder influences which may cause management to seek to manipulate the financial performance and did not note any;
- Based on this understanding we designed our audit procedures to identify non-compliance with such laws and
  regulations. Our procedures involved the review of minutes of meetings of the Board of Directors; review of
  compliance reports; review of correspondence with the Guernsey Financial Services Commission; making
  inquiries of those charged with governance; and performance of journal entry testing based on our risk
  assessment and understanding of the business, with a focus on non-standard journals and those relating to
  areas with an identified associated fraud risk, as described above.

A further description of our responsibilities for the audit of the financial statements is located on the

Financial Reporting Council's website at https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

#### Use of our report

This report is made solely to the Incorporated Cell's members, as a body, in accordance with Section 262 of The Companies (Guernsey) Law 2008 and Paragraph 4.2(4) of the Authorised Collective Investment Schemes (Class B) Rules and Guidance, 2021. Our audit work has been undertaken so that we might state to the Incorporated Cell 's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Incorporated Cell and the Incorporated Cell's members as a body, for our audit work, for this report, or for the opinions we have formed.

Signed by: Ernst & Jane U

Ernst & Young LLP Guernsey, Channel Islands Date: 09 October 2024

# m

# Caleo Global Flexible Fund IC Limited

### Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### Custodian's Report to the Members of Caleo Global Flexible Fund IC Limited

In our opinion, the Cell has, in all material aspects, been managed for the year ended 30 June 2024 in accordance with the provisions of the Principal Documents, Scheme Particulars and The Authorised Collective Investment Schemes (Class B) Rules and Guidance, 2021.

Mildzon. (Des

For and on behalf of Northern Trust (Guernsey) Limited 2 October 2024

# Annual Report and Audited Financial Statements for the year ended 30 June 2024

## **Supplementary Information**

		30.06.24	30.06.23
1.	NUMBER OF SHARES OUTSTANDING Class A	38,017,699	43,336,230
2.	<b>NET ASSET VALUE PER SHARE - USD</b> Class A	1.51	1.39
3.	HIGHEST/LOWEST PRICE - USD* Class A	1.51/1.30	1.40/1.19
4.	NUMBER OF SHARES SUBSCRIBED Class A	1,379,111	288,230
5.	NUMBER OF SHARES REDEEMED Class A	6,697,642	7,689,736

\* The highest/lowest price is based on prices from prior year end to current year end, being 30.06.2024.

# Annual Report and Audited Financial Statements for the year ended 30 June 2024

## Portfolio Statement

			% of Net
	Holdings	Fair Value USD	Assets
Financial assets at fair value through profit or loss		030	
Collective Investment Schemes: 92.89% (2023: 89.54%)			
Asset Allocation Funds			
MiPlan Global Macro IC Limited (A Class)	737,293	9,856,644	17.21
Total Asset Allocation Funds		9,856,644	17.21
Equity Funds			
Dodge & Cox Worldwide Funds plc - Global Stock Fund USD Acc	116,661	4,143,811	7.24
Fundsmith Equity Fund	316,524	2,880,653	5.03
Invesco S&P Smallcap 600 Revenue ETF	30,800	1,234,155	2.16
iShares Edge MSCI World Value Factor UCITS ETF	81,791	3,461,657	6.04
iShares MSCI World ETF	44,516	6,565,665	11.46
Sanlam Centre American Select Equity Fund - Class C USD	556,470	1,441,479	2.52
Schwab U.S. Dividend Equity ETF	36,975	2,875,176	5.02
Total Equity Funds		22,602,596	39.47
Fixed Income Funds			
iShares \$ Treasury Bond 0-1yr UCITS ETF USD (Acc)	33,940	3,768,019	6.58
iShares Global Govt Bond UCITS USD	831,954	3,684,516	6.43
JPMorgan Ultra-Short Income ETF	73,599	3,714,542	6.49
PIMCO Active Bond Exchange-Traded Fund	44,670	4,068,544	7.10
Sphereinvest Global UCITS ICAV - Global Credit Strategies Fund	20,442	4,462,557	7.79
Vanguard Short-Term Bond ETF	13,577	1,041,356	1.82
Total Fixed Income Funds		20,739,534	36.21
Total Collective Investment Schemes		53,198,774	92.89
Financial assets at fair value through profit or loss		53,198,774	92.89
Other Net Assets: 7.11% (2023: 3.91%)		4,070,141	7.11
Net Assets Attributable to Holders of Participating Redeemable Share	2S	57,268,915	100.00

# Annual Report and Audited Financial Statements for the year ended 30 June 2024

## **Statement of Financial Position**

	Notes	Year ended 30.06.24 <u>USD</u>	Year ended 30.06.23 <u>USD</u>
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	7	616,507	2,414,906
Securities sold receivable	3	3,549,439	-
Financial assets at fair value through profit or loss	6	53,198,774	57,698,702
Dividend receivable	3	21,330	-
Deposit interest receivable	3	2,347	14,403
Other receivables	8	430	1,316
	_	57,388,827	60,129,327
Total assets	_	57,388,827	60,129,327
LIABILITIES			
CURRENT LIABILITIES			
Due on redemption of participating redeemable shares	3	42,173	-
Other payables	9	77,639	83,420
Liabilities (excluding net assets attributable to holders of			
participating redeemable shares)	_	119,812	83,420
Net assets attributable to holders of participating redeemable shares	3&11	57,268,915	60,045,807
Total liabilities	_	57,388,727	60,129,227
SHAREHOLDERS' EQUITY			
Management shares	10	100	100
Total equity		100	100
Total equity and liabilities	=	57,388,827	60,129,327
Net asset value per participating redeemable share			
Class A	11	1.51	1.39
The notes 1 to 16 on pages 18 to 34 form part of these financial statements.			

The notes 1 to 16 on pages 18 to 34 form part of these financial statements.

These financial statements were authorised for issue by the Board of Directors on 2 October 2024 and signed on its behalf by:

M

Marie Curutchet Director

Robert Rhodes Director

### Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### **Statement of Comprehensive Income**

		Year ended 30.06.24	Year ended 30.06.23
	Notes	<u>USD</u>	USD
INCOME			
Net realised losses on financial assets at fair value			
through profit or loss	6	(1,942,007)	(5,594,809)
Change in unrealised gains on financial assets at fair value			
through profit or loss	6	6,834,786	10,761,009
Net gains on financial assets at fair value through profit or loss		4,892,779	5,166,200
Deposit interest		52,281	132,327
Dividend income		516,644	451,500
Other foreign exchange gains/(losses)	_	12,012	(47,811)
Total net income		5,473,716	5,702,216
OPERATING EXPENSES			
Audit fee		(10,661)	-
Management, Investment Management and Administration fee	13	(192,514)	-
Management and Administration fee	13	(3,637)	(205,176)
Investment Management fee	13	(11,463)	(641,076)
Sub-Investment Management fee	13	(467,535)	-
Custodian fee	13	(25,608)	(15,613)
Directors' fee	13	(9,781)	-
Sundry expenses	_	(8,949)	(4,884)
Total operating expenses		(730,148)	(866,749)
Net profit before tax		4,743,568	4,835,467
Withholding tax		(149,681)	(112,451)
Increase in net assets attributable to holders of participating			
redeemable shares from operations	_	4,593,887	4,723,016

The notes 1 to 16 on pages 18 to 34 form part of these financial statements.

All items in the above statement derive from continuing operations. There is no difference between the increase in net assets attributable to holders of participating redeemable shares and comprehensive income.

### Annual Report and Audited Financial Statements for the year ended 30 June 2024

**Statement of Cash Flows** 

	Year ended 30.06.24 <u>USD</u>	Year ended 30.06.23 <u>USD</u>
CASH FLOW FROM OPERATING ACTIVITIES		
Increase in net assets attributable to holders of participating redeemable		
shares from operations	4,593,887	4,723,016
ADJUSTMENTS FOR:		
Net realised losses on financial assets at fair value through profit or loss	1,942,007	5,594,809
Net change in unrealised gains on financial assets at fair value through profit or loss	(6,834,786)	(10,761,009)
Effect of foreign exchange rate on cash	14,287	14,280
Deposit interest	(52,281)	(132,327)
Dividend income	(516,644)	(451,500)
Withholding tax	149,681	112,451
Operating loss before working capital changes	(703,849)	(900,280)
Net decrease/(increase) in other receivables	886	(546)
Net decrease in other payables	(5,781)	(35,558)
Purchase of financial assets at fair value through profit or loss*	(28,485,350)	(22,113,665)
Sale of financial assets at fair value through profit or loss*	34,328,618	29,610,675
Dividend received	345,633	339,049
Deposit interest	64,337	118,670
Net cash generated from operating activities	5,544,494	7,018,345
CASH FLOW FROM FINANCING ACTIVITIES		
Cash received from issuance of participating redeemable shares	1,949,059	434,943
Cash paid on redemption of participating redeemable shares	(9,277,665)	(10,249,332)
Net cash used in financing activities	(7,328,606)	(9,814,389)
Net decrease in cash and cash equivalents	(1,784,112)	(2,796,044)
Cash and cash equivalents at the beginning of the year	2,414,906	5,225,230
Effect of foreign exchange rate on cash and cash equivalents	(14,287)	(14,280)
Cash and cash equivalents at the end of the year	616,507	2,414,906

The notes 1 to 16 on pages 18 to 34 form part of these financial statements.

\* Purchases and sales of financial assets at fair value through profit or loss have been included as operating activity as this is the primary activity of the Cell.

# Annual Report and Audited Financial Statements for the year ended 30 June 2024

### Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares

	Year ended	Year ended
Note	30.06.24	30.06.23
	<u>USD</u>	<u>USD</u>
	60,045,807	65,130,877
	1,949,059	434,943
	(9,319,838)	(10,243,029)
-	4,593,887	4,723,016
11	57,268,915	60,045,807
		Note 30.06.24 <u>USD</u> 60,045,807 1,949,059 (9,319,838) 4,593,887

The notes 1 to 16 on pages 18 to 34 form part of these financial statements.



### Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### Notes to the Financial Statements

#### 1. General information

The Caleo Global Flexible Fund IC Limited (the "Incorporated Cell" or "Cell") with company number 56161, is a Guernsey registered, Limited Liability Incorporated Cell of the Momentum Mutual Fund ICC Limited (the "Company").

The primary objective of the Cell is capital appreciation in real terms over the investment horizon. The Cell is ideally suited to investors with a moderate to aggressive risk tolerance (measured in the base currency of the Cell) over an investment cycle of five years or longer. The diversified portfolio invests into a wide range of asset classes including cash, fixed income, equities, property, commodities and alternative investment strategies. As this portfolio is global in nature, exposure will be taken in a wide range of currencies and markets.

The Cell intends to achieve its investment objective through a diversified global portfolio that invests, via other collective investment funds, exchange traded funds and transferable securities across a broad range of asset classes and currencies in varying proportions over time. These classes include international equities, bonds, alternative strategies, property, money market instruments, commodities and multi asset portfolios.

The Cell's investment activities are managed by Momentum Wealth International Limited (the "Manager"), with the investment management delegated to Momentum Global Investment Management Limited (the "Investment Manager") and Caleo Capital (Pty) Ltd acting as Sub-Investment Manager.

On 10 July 2023, amendments were made to the Supplemental Prospectus of the Cell, and the following changes were implemented during the year:

- Pursuant to the Management Agreement, the Manager shall be entitled to the payment of a fee of 0.35% of the NAV of the Cell per annum (subject to a minimum fee of USD 40,000 per annum) for the services rendered in connection with the Cell. The Management Fee will accrue as at each Valuation Point, based on the current valuation and is payable monthly in arrears. The Manager shall settle the fees of the Administrator and the Investment Manager on behalf of the Cell from the proceeds of the Management Fee.
- Pursuant to the terms of the Sub-Investment Management Agreement, the Sub-Investment Manager shall be entitled to a fee of 0.85% of the NAV of the Cell per annum for the services rendered in connection with the Cell.
- A Director's fee of USD 10,000 per annum shall apply in respect of the Cell. In addition, the Directors shall be entitled to be repaid for all reasonable out of pocket expenses properly incurred by them in the performance of their duties to the Cell.
- The Company and the Cell have been approved for promotion in South Africa by the Financial Sector Conduct Authority (previously the Financial Services Board) of South Africa under section 65 of the Collective Investment Schemes Control Act 2002.

The financial statements were authorised for issue by the Board of Directors on 2 October 2024.

#### 2. Material accounting policies

The principal accounting policies detailed below have been consistently applied in the preparation of the financial statements.

#### 2.1 Basis of preparation

The financial statements for the Incorporated Cell have been prepared on a going concern basis, in accordance with International Financial Reporting Standards ("IFRS"). The financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets and financial liabilities at fair value through profit or loss (including derivative financial instruments).

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates, which are disclosed in note 4 of the Incorporated Cell's financial statements. It also requires the Board of Directors to exercise its judgement in the process of applying the Incorporated Cell's accounting policies.

### Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### Notes to the Financial Statements

#### 2. Material accounting policies (continued)

#### 2.1 Basis of preparation (continued)

#### Going concern

At the time of approving the financial statements, the Board has assessed redemption levels and there have been no significant redemptions. The Board has also considered the liquid nature of the investment portfolio, the absence of any borrowings or commitments and the economic viability of the Cell which is driven by its net asset value.

After careful consideration, the Board is satisfied that the Cell has sufficient liquidity to meet its liabilities for the period to 31 December 2025 and therefore it is appropriate to adopt the going concern basis in preparing the financial statements and they have a reasonable expectation that the Cell will continue in existence as a going concern.

#### 2.2 Adoption of new and revised accounting standards

The Directors have adopted a policy of applying new standards and interpretations when they become effective.

Standards, amendments and interpretations effective during the year

The following accounting standards, amendments and interpretations became effective for the first time in this reporting period:

Periods beginning on or after 1 January 2023:

(a) IAS 8 - Definition of Accounting Estimates - Effective from 1 January 2023 - Amendments regarding classification of liabilities and disclosure of accounting policies.

(b) IAS 1 - Disclosure Initiative - Accounting Policies - Effective from 1 January 2023 - Amendments to help entities apply materiality judgements to accounting policy disclosure.

IAS 1 has been amended to replace the requirement for entities to disclose their significant accounting policies with a requirement to disclose material accounting policies. The policies presented in the financial statements for the year ended 30 June 2023 have been assessed, and those that are considered material have been disclosed for the year ended 30 June 2024.

The adoption of these standards has not had a material impact on the financial statements of the Incorporated Cell.

#### Standards, amendments and interpretations in issue not yet effective

A number of new standards, amendments and interpretations are effective for annual periods beginning on or after 1 January 2024 and have not been early adopted in preparing these financial statements. In particular, these include:

(a) IFRS S1 and IFRS S2 – Sustainability Disclosure Standards – Effective from 1 January 2024 – New standards regarding the disclosure of sustainability-related financial information.

The Board anticipates that the adoption of these standards, which will be adopted in the period which they become effective, will not have a material impact on the financial statements of the Cell.

#### 2.3 Foreign currency translation

#### (a) Functional and presentation currency

The currency in which the financial information is shown in the financial statements of the Incorporated Cell is deemed to be its functional and presentational currency. In arriving at the functional currency, the Directors have considered the primary economic environment of the Incorporated Cell, and in doing so have considered the currency in which the original capital was raised, any distributions are to be made, performance is evaluated and ultimately, the currency in which capital would be returned on break up basis. They have also considered the currency to which the majority of the underlying investments are exposed and liquidity is managed. The Directors are of the opinion that the currency selected best represent the functional currency.

## Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### Notes to the Financial Statements

#### 2. Material accounting policies (continued)

#### 2.3 Foreign currency translation (continued)

#### (b) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Statement of Comprehensive Income. Translation differences on non-monetary financial assets and liabilities such as equities at fair value through profit or loss are recognised in the Statement of Comprehensive Income within the fair value net gain or loss.

#### 2.4 Financial assets and financial liabilities at fair value through profit or loss

#### (a) Classification

The Incorporated Cell classifies its investments in Collective Investment Schemes, equities and related derivatives as financial assets or financial liabilities at fair value through profit or loss. These financial assets and financial liabilities are classified by the Board of Directors at fair value through profit or loss at inception. The Incorporated Cell does not classify any derivatives as hedges in a hedging relationship. Financial assets and financial liabilities are designated at fair value through profit or loss at inception, are managed, and their performance evaluated on a fair value basis in accordance with the Incorporated Cell's documented investment strategy. The Incorporated Cell's policies are for the Investment Manager and the Board of Directors to evaluate the information about these financial assets on a fair value basis together with other related financial information.

#### (b) Recognition/derecognition

Regular-way purchases and sales of investments are recognised on the trade date of the underlying security, so long as the underlying transaction has been confirmed by the relevant counterparty as at the Statement of Financial Position date. Investments are derecognised when the rights to receive cash flows from the investments have expired or the Incorporated Cell has transferred substantially all risks and rewards of ownership.

#### (c) Measurement

Financial assets and financial liabilities at fair value through profit or loss are initially recognised at fair value. Transaction costs are expensed in the Statement of Comprehensive Income of the Incorporated Cell. Subsequent to initial recognition, all financial assets and financial liabilities at fair value through profit or loss are measured at fair value. Gains and losses arising from changes in the fair value of the 'financial assets or financial liabilities at fair value through profit or loss' category are presented in the Statement of Comprehensive Income in the period in which they arise.

#### (d) Fair value estimation

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of financial assets and liabilities traded in active markets (such as publicly traded derivatives and trading securities) are based on quoted market prices at the close of trading on the reporting date. The Incorporated Cell adopted to utilise the last traded market price for both financial assets and financial liabilities where the last traded price falls within the bid-ask spread. In circumstances where the last traded price is not within the bid-ask spread, management will determine the point within the bid-ask spread that is most representative of fair value. As a practical expedient to establish fair value within the bid-ask spread, management will use mid-market pricing. The market price used for assets which are not traded in active markets are those as supplied by their fund administrators.

### Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### Notes to the Financial Statements

#### 2. Material accounting policies (continued)

#### 2.5 Offsetting financial instruments

Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis, or realise the asset and settle the liability simultaneously. The Cell entered into a ISDA Master Netting Agreement with Northern Trust (Guernsey) Limited effective 17 June 2024.

#### 2.6 Forward currency contracts

Forward foreign currency contracts are treated as derivative contracts and as such are recognised at fair value on the date on which they are entered into and subsequently remeasured at their fair value. Fair value is determined by rates in active currency markets. All derivatives are carried as assets when fair value is positive and as liabilities when fair value is negative. The gain or loss on remeasurement to fair value is recognised immediately through profit or loss in the Statement of Comprehensive Income within other losses and gains in the period in which they arise.

#### 2.7 Cash and cash equivalents

Cash and cash equivalents include cash in hand, demand deposits and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts.

#### 2.8 Other financial instruments

For other financial instruments, including amounts due to and from brokers and all receivables and payables, the carrying amounts as shown in the Statement of Financial Position approximate to fair value due to the short-term nature of these financial instruments.

#### 2.9 Share capital

The Incorporated Cell has an authorised share capital of 100 management shares of GBP1.00 each and an unlimited number of no par value participating redeemable shares.

#### (a) Management shares

Management shares were issued to comply with the Guernsey Company Law, prior to its revision in 2008, under which there had to be a class of non-redeemable shares in issue in order that participating redeemable shares may be issued. The management shares are beneficially owned by the Manager, do not carry any right to dividends, are only entitled to vote at shareholder meetings where there are no participating redeemable shares in issue within the Incorporated Cell and are only entitled to return of capital on the winding up of the Incorporated Cell.

The Incorporated Cell has issued 100 management shares.

#### (b) Participating redeemable shares

The Incorporated Cell's capital is represented by participating redeemable shares with no par value each carrying one vote, no matter which share class. Each share class carries identical rights, the only difference between the classes being either the management fee or the distribution partner fee which is charged to each class. These fees are disclosed in note 13.

The participating redeemable shares are redeemable at the holder's option and are classified as financial liabilities. Participating redeemable shares can be put back to the Incorporated Cell at any time for cash equal to a proportionate share of the Incorporated Cell's net asset value. The participating redeemable share is carried at the redemption amount that is payable at the Statement of Financial Position date if the holder exercises the right to put the share back to the Incorporated Cell.

### Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### Notes to the Financial Statements

#### 2. Material accounting policies (continued)

#### 2.9 Share capital (continued)

#### (b) Participating redeemable shares (continued)

All participating redeemable shares will rank equally for all dividends and other distributions, as adjusted to reflect any differences in the fees to which each class of participating redeemable share is subject. They are entitled to payment of a proportionate share based on the Cell's net asset value per share on the redemption date. The Cell has no restrictions or specific capital requirements on the subscriptions and redemptions of shares. The relevant movements are shown on the Statement of Changes in Net Assets Attributable to Holders of Participating Redeemable Shares. In accordance with the Cell's investment objectives, and its risk management policies, the Cell endeavours to invest the subscriptions received in appropriate investments while maintaining sufficient liquidity to meet redemptions, such liquidity being augmented by short-term borrowings or disposal of listed securities where necessary.

To determine the net asset value of the Cell for subscriptions and redemptions, investments have been valued based on the last traded market prices as of the close of business on the relevant trading day.

#### 2.10 Capital risk management

The fair value of the Cell's financial assets and financial liabilities approximate to its carrying amounts at the reporting date. For the purposes of this disclosure, shares are considered to be capital.

The Incorporated Cell's objectives when managing capital is to safeguard their ability to continue as a going concern in order to provide returns for shareholders. There are no externally imposed capital requirements on the Incorporated Cell. The Incorporated Cell has no intention to borrow, other than to fund short-term liquidity requirements. The Incorporated Cell may arrange an overdraft facility for such purposes.

#### 2.11 Interest and dividend income

Dividend income is recognised when the right to receive payment is established. All deposit interest and other income is accounted for on an accrual basis.

#### 2.12 Expenses

Expenses are accounted for on an accruals basis and all amounts have been allocated to the Statement of Comprehensive Income.

#### 2.13 Custodian bank charges

Custodian bank charges include additional fees on top of the asking price of the security. The bid-asking spread is not disclosed as part of a custodian bank charge. This spread is included in the Statement of Comprehensive Income within the fair value net gain or loss.

#### 2.14 Taxation

The Cell has been granted Exempt Status under the terms of The Income Tax (Exempt Bodies) (Guernsey) Ordinance, 1989 to income tax in Guernsey. Its liability is an annual fee of £1,600 (2023: £1,200).

The Cell incurs withholding taxes imposed by certain countries on investment income and capital gains. Such income or gains are recorded gross of withholding taxes in the Statement of Comprehensive Income. Withholding taxes are shown as a separate item in the Statement of Comprehensive Income.

# **Caleo Global Flexible Fund IC Limited** Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### **Notes to the Financial Statements**

#### 3. Financial risk management

#### 3.1 Strategy in using financial instruments

The Cell's activities and investment objectives expose it to a variety of financial risks: market risk (which is made up of price risk, interest rate risk and currency risk), credit risk and liquidity risk (including cash flow risk). The Cell's overall risk management programme seeks to maximise the return derived for the level of risk to which the cell is exposed and focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Cell's financial performance.

The Cell will not include derivative instruments with the exception of investments in forward foreign currency exchange contracts for the purpose of mitigating exchange rate risk against both the benchmark and the base currency but not for speculative purposes or otherwise. Unlisted derivative instruments will be limited to unlisted forward currency, interest rate, index swap or exchange rate swap transactions. No uncovered positions will be allowed. Gearing and leveraging for investment purposes will not be allowed.

The following policies and procedures to mitigate risk have been in place throughout the year.

#### 3.2 Market price risk

Market price risk is the risk that the fair value of future cash flows will fluctuate because of changes in market prices, other than those arising from currency or interest rate risk. The Cell is subject to market price risk as it trades primarily in collective investment schemes. Through its investment in traded securities and instruments the Cell is subject to market movements in equity and bond markets.

All investments present a risk of loss of capital. The Investment Manager moderates this risk through a careful selection of securities and other financial instruments within specified limits. The maximum risk resulting from financial instruments is determined by the fair value of the financial instruments. The Cell's overall market positions is monitored by the Investment Manager and is reviewed by the Board of Directors.

The Cell's market price risk is managed through diversification of the investment portfolio by exposures to varying product categories, hence, concentration of risk is minimised. At the year end, the financial assets at fair value through profit or loss, which are subject to market price risk, are as follows:

As at 30 June		2024		2023
	Fair Value	% of	Fair Value	% of
	<u>USD</u>	net assets	USD	net assets
Collective Investment Schemes	53,198,774	92.89	53,766,768	89.54
Property and Infrastructure Investment Trusts and ETFs		-	3,931,934	6.55
	53,198,774	92.89	57,698,702	96.09

The Cell's market risk is affected by three main components: changes in actual market prices, interest rate and foreign currency exchange rates movements. Interest rate and foreign currency movements are covered in notes 3.3 and 3.5, respectively. If the market indices increased or decreased by 10% with all other variables held constant, the increase or decrease respectively in net assets attributable to holders of participating redeemable shares would amount to:

As at 30 June	2024 Change in fair value <u>USD</u>	2023 Change in fair value <u>USD</u>
Collective Investment Schemes	5,319,877	5,376,677
Property and Infrastructure Investment Trusts and ETFs	-	393,193
	5,319,877	5,769,870

### Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### Notes to the Financial Statements

#### 3. Financial risk management (continued)

#### 3.3 Interest rate risk

The Cell's interest-bearing financial assets and liabilities expose it to risks associated with the effects of fluctuations in the prevailing levels of market interest rates on its financial position and cash flows.

The majority of the Cell's financial assets and liabilities are non-interest bearing. As a result, the Cell is not subject to significant amounts of risk due to fluctuations in the prevailing levels of market interest rates. Any excess cash and cash equivalents are invested at short-term market interest rates.

The table below summarises the Cell's exposure to interest rate risk. It includes the Cell's assets and trading liabilities at fair values, all of which have contractual re-pricing or maturity dates within one month.

	2024	2023
	<u>USD</u>	<u>USD</u>
Net financial assets on which no interest is paid	56,652,408	57,630,901
Net floating rate financial assets	616,507	2,414,906

Should interest rates have increased/decreased by 50 basis points with all other variables remaining constant, the increase/decrease in the net assets attributable to participating redeemable shareholders would amount to approximately:

As at 30 June	2024	2023
	USD	USD
Movement in net floating rate financial assets	3,083	12,075

#### 3.4 Cash flow risk

The Cell holds a minimal amount of cash and cash equivalents that expose the Cell to cash flow interest rate risk. The risk exposure here is deemed minimal.

#### 3.5 Currency risk

Currency risk is the risk that the fair value of future cash flows will fluctuate as a result of changes in foreign currency exchange rates. The Cell holds assets, including investments, denominated in currencies other than the US Dollar; the functional currency, therefore, is exposed to currency risk. The exposures are based on the currencies of the underlying assets in the Cell. Where the Cell invests via Collective Investment Schemes, the funds are treated as a single asset with its currency of exposure being assumed to be its reporting currency.

The table below summarises the Cell's exposure to currency risks:

As at 30 June	2024	2023
	USD	<u>USD</u>
Net ZAR exposure	(4,293)	(1,966)
Net GBP exposure	2,865,080	7,802,616

In accordance with the Cell's policy, the Investment Manager monitors the Cell's currency position on a regular basis, and the Board of Directors reviews it periodically. The Cell has the ability to enter into forward foreign exchange contracts in an attempt to mitigate any significant currency risk, however, to date, the Investment Manager and Board of Directors have deemed that such contracts have not been necessary.

# **Caleo Global Flexible Fund IC Limited** Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### Notes to the Financial Statements

#### 3. Financial risk management (continued)

#### 3.5 Currency risk (continued)

Should the Cell's functional currency have strengthened, or weakened, by 5% against other currencies to which it is exposed and all other variables, including the price of all investments, had held constant, the net asset attributable to preference shareholders would have increased, or decreased, as follows:

As at 30 June	2024 <u>USD</u>	2023 <u>USD</u>
ZAR exposure	(215)	(98)
GBP exposure	143,254	390,131

#### 3.6 Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation.

There is a risk that an investee company may be unable to satisfy a valid redemption request made by a Cell. The Directors consider that the Investment Manager mitigates this risk by way of its investment process, as described in note 3.2. No such redemption problems have been encountered.

All transactions in listed securities are settled or paid for upon delivery using approved brokers. Delivery of securities sold is only made once the broker has received payment. Payment is made on a purchase once the securities have been received by the broker. Given the relatively short settlement period and the high credit quality of the brokers used, the risk here is considered to be minimal.

The Cell manages its exposure to credit risk associated with its cash deposits by selecting Northern Trust (Guernsey) Limited as the counterparty to hold all cash deposits for the cell. The Northern Trust Company is a wholly owned subsidiary of the Northern Trust Corporation. The credit rating for Northern Trust Corporation from Standard and Poor's is A+. The credit rating from Moody's is A2.

The Cell's maximum exposure to credit risk is the carrying value of the assets on the Statement of Financial Position.

#### 3.7 Liquidity risk

Liquidity risk is the risk that the Cell will encounter difficulty in meeting obligations associated with its financial liabilities. The main liquidity risk is the risk that the Cell may be unable to recover funds invested through the usual redemption processes which may result in the Cell having insufficient funds to settle a transaction on the due date. Due to the nature of the Cell, the majority of investments held are in marketable securities that are readily tradable and have reported no warnings regarding their ability to process redemptions as normal.

Within the prospectus, the Cell has the ability to borrow to meet short-term liquidity requirements, up to the value of 10% of the NAV of the Cell. To date, the Cell has not had to enter into such arrangements.

### Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### Notes to the Financial Statements

#### 3. Financial risk management (continued)

#### 3.7 Liquidity risk (continued)

The table below analyses the Cell's financial assets and financial liabilities into relevant maturity groupings based on the remaining period at the statement of financial position date to the contractual maturity date. The amounts in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances, as the impact of discounting is not significant.

		Between 1		
	Less than 1	and	2024	2023
	month	12 months	Total	Total
	<u>USD</u>	USD	<u>USD</u>	<u>USD</u>
Financial assets at fair value through profit or loss	53,198,774	-	53,198,774	57,698,702
Cash and cash equivalents	616,507	-	616,507	2,414,906
Securities sold receivable	3,549,439	-	3,549,439	-
Dividend receivable	21,330	-	21,330	-
Deposit interest receivable	2,347	-	2,347	14,403
Other receivables	330	-	330	1,216
Due on redemption of participating	(42,173)	-	(42,173)	-
Other payables	(77,639)	-	(77,639)	(83,420)
Net assets attributable to holders of				
participating redeemable shares	(57,268,915)	-	(57,268,915)	(60,045,807)
Net liquidity position	-	-	-	-

Participating redeemable shares are redeemed on demand at the holder's option. However, the Board of Directors does not envisage that the contractual maturity disclosed in the table above will be representative of the actual cash flows, as holders of these instruments typically retain them for the medium to long term.

#### 3.8 Management of capital

The Board, with the assistance of the Investment Manager, manages the capital of the Cell in accordance with the investment objectives and policies. The overall strategy of the Cell remains unchanged.

The Cell has no externally imposed capital requirements.

#### 3.9 Fair value disclosure

In the opinion of the Directors, there are no material differences between the net asset values of the underlying assets and the fair values of the financial assets and liabilities of the Cell.

#### 4. Critical accounting estimates and judgements

The fair value of investments is considered to be the quoted, active market prices, or prices supplied by the fund administrators of the Cell's underlying investments.

Management makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities are outlined below.

### Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### Notes to the Financial Statements

#### 4. Critical accounting estimates and judgements (continued)

The fair value of investments in investee funds that are not quoted in an active market is determined primarily by reference to the latest available redemption price of such units for each investee fund, as determined by the administrator of such investee fund. The Investment Manager may make adjustments to the reported net asset value of various investee funds based on considerations such as:

- the liquidity of the investee fund or its underlying investments;
- the value date of the net asset value provided;
- any restrictions on redemptions; and
- the basis of accounting and, in instances where the basis of accounting is other than fair value, fair valuation information provided by the investee fund's advisors.

The prices are reviewed by the Investment Manager on a periodic basis. The Cell does not hold any Level 3 investments.

#### 5. Portfolio analysis

The Cell's portfolio is organised by focusing on the type of security held and then secondarily by geographical analysis based on the location of the investment.

The Cell operates using the main sector types disclosed in note 3.2 and the following main geographical areas:

	2024 <u>USD</u>	2023 <u>USD</u>
Guernsey	9,856,644	-
Ireland	20,962,039	28,138,016
Luxembourg	-	7,340,367
United Kingdom	2,880,654	6,030,428
United States of America	19,499,437	16,189,890
	53,198,774	57,698,701

The geographical segment for the portfolio is considered to be the country of incorporation of the financial assets.

### Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### Notes to the Financial Statements

#### 6. Financial assets at fair value through profit or loss

	2024	2023
	USD	USD
Financial assets at fair value through profit or loss:		
Collective Investment Schemes	53,198,774	53,766,768
Property and Infrastructure Investment Trusts and ETFs	-	3,931,934
Total financial assets at fair value through profit or loss	53,198,774	57,698,702
	2024	2023
	USD	USD
Movement on financial assets at fair value through profit or loss		
Fair value of financial assets at the beginning of the year	57,698,702	60,029,512
Purchases of financial assets	28,485,350	22,113,665
Sales of financial assets	(37,878,057)	(29,610,675)
Realised losses on sale of financial assets	(1,942,007)	(5,594,809)
Movement in unrealised gains on revaluation of financial assets	6,834,786	10,761,009
Fair value of financial assets at the end of the year	53,198,774	57,698,702
Comprising:		
Cost at the end of the year	48,546,435	59,881,149
Unrealised gains/(losses) at the end of the year	4,652,339	(2,182,447)
	53,198,774	57,698,702

IFRS 13 requires the Cell to classify fair value hierarchy that reflects the significance of the inputs used in making the measurements. The hierarchy has the following levels:

- Level 1 quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access
  at the measurement date;
- Level 2 inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The level in the fair value hierarchy, within which the fair value measurement is categorised in its entirety, is determined on the basis of the lowest level input that is significant to the fair value measurement in its entirety. For this purpose, the significance of an input is assessed against the fair value measurement in its entirety. If a fair value measurement uses observable inputs that require significant adjustment based on unobservable inputs, that measurement is a Level 3 measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgement, considering factors specific to the asset or liability.

The determination of what constitutes 'observable' requires significant judgement by the Board. The Board considers observable market data that is readily available, readily distributed or updated, reliable and verifiable, not proprietary and provided by independent sources that are actively involved in the relevant market.

The investments classified as Level 1 consist of financial assets that are actively traded with fair values readily available from recognised exchanges. The Level 1 hierarchy may also include investments in funds that are priced by the underlying administrator where the Cell considers it to be the most advantageous market and would enter into transactions based on those prices.

The investments classified as Level 2 are investments in funds that are actively traded and priced less frequently than monthly but not greater than quarterly for which fair values are obtained from the underlying administrator or fund manager.

### Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### Notes to the Financial Statements

#### 6. Financial assets at fair value through profit or loss (continued)

The investments classified as Level 3 are investments that are illiquid investments and investments that are traded but priced less frequently than quarterly.

The following table presents the Cell's financial assets and financial liabilities measured at fair value by level within the valuation hierarchy as of 30 June 2024 and 30 June 2023.

30 June 2024	Level 1 <u>USD</u>	Level 2 <u>USD</u>	Level 3 <u>USD</u>	Total <u>USD</u>
Financial assets at fair value through profit or loss				
Collective Investment Schemes	53,198,774	-	-	53,198,774
	53,198,774	-	-	53,198,774
30 June 2023	Level 1	Level 2	Level 3	Total
	<u>USD</u>	<u>USD</u>	USD	USD
Financial assets at fair value through profit or loss				
Collective Investment Schemes	53,766,768	-	-	53,766,768
Property and Infrastructure Investment Trusts and ETFs	3,931,934	-	-	3,931,934
	57,698,702	-	-	57,698,702

There were no movements or reclassifications of investments within the levels of the fair value hierarchy during the years ended 30 June 2024 and 30 June 2023.

The Cell's cash and cash equivalents and short-term receivables and payables are recorded at carrying value which approximates fair value.

#### 7. Cash and cash equivalents

For the purposes of the Statement of Cash Flows, cash and cash equivalents comprise the following balances with original maturity of less than 90 days:

	2024	2023
	USD	<u>USD</u>
Cash at bank	616,507	2,414,906
	616,507	2,414,906

#### 8. Other receivables

	2024 <u>USD</u>	2023 <u>USD</u>
Prepayments	330	1,216
Management shares receivable	100	100
	430	1,316

# Annual Report and Audited Financial Statements for the year ended 30 June 2024

### Notes to the Financial Statements

#### 9. Other payables

	2024 <u>USD</u>	2023 <u>USD</u>
Management, Investment Management and Administration fee payable	15,555	-
Management and administration fee payable	-	16,088
Investment management fee payable	-	49,891
Sub-Investment Management fee payable	37,126	-
Custodian fee payable	2,048	4,788
Directors' fee payable	9,781	-
Audit fee payable	9,860	9,346
Sundry fees payable	3,269	3,307
	77,639	83,420

#### 10. Share capital

The Cell has an authorised share capital of 100 Management shares of USD1.00 each and an unlimited number of no par value participating redeemable shares.

Management Shares in Issue	2024 <u>USD</u>	2023 <u>USD</u>
Management shares	100	100
Participating Padaomable Shares in Issue Class A	Year ended 30 June 2024	Year ended 30 June 2023
Participating Redeemable Shares in Issue - Class A		
Balance at the beginning of the year Issue of participating redeemable shares	43,336,230 1,379,111	50,737,736 288,230
Redemption of participating redeemable shares	(6,697,642)	(7,689,736)
Balance at the end of the year	38,017,699	43,336,230

#### 11. Net asset value per participating redeemable share

	NAV per	Net assets	Shares in	NAV per	Net assets	Shares in
	share	attributable	issue	share	attributable	issue
As at 30 June	2024	2024	2024	2023	2023	2023
	<u>USD</u>	<u>USD</u>		USD	<u>USD</u>	
Class A	1.51	57,268,915	38,017,699	1.39	60,045,807	43,336,230

#### 12. Dividends payable to participating redeemable shareholders

No dividends were paid during the year and the Board does not intend to pay any dividends (2023: Nil). All available income will be reinvested.

### Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### Notes to the Financial Statements

#### 13. Related party transactions

Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial or operational decisions.

#### 13.1 Management and Administration fee

The Cell is managed by Momentum Wealth International Limited (the "Manager"), a management company incorporated in Guernsey, providing management services to the Cell under the terms of the management agreement in place.

The Manager was entitled to receive the following Management and Administration fee, chargeable on a sliding scale, payable monthly in arrears, it was based on the current valuation and subject to a minimum annual fee of USD 22,000 or currency equivalent up until the end of 9 July 2023.

Fee% of NAV per annum	<u>Cell NAV</u>
0.35%	Up to USD 30m
0.30%	From USD 30m to USD 60m
0.25%	Over USD 60m
Management and Administration fee charged during the year and accrued at year end:	
	202/1 2023

	2024	2023
	<u>USD</u>	USD
Charged during the year	3,637	205,176
Accrued at year end	-	16,088

#### 13.2 Investment Management fee

The Manager has appointed an Investment Manager, Momentum Global Investment Management Limited, a UK registered company, to manage the investment portfolio of the Cell.

Up until 9 July 2023, the Investment Manager was entitled to receive a fee (the "Investment Management fee"), equal to 1.00% of the NAV of the Cell attributable to the Class A USD Shares per annum. The Investment Management fee accrued at each valuation point, based on the current valuation, subject to a minimum annual fee of USD 20,000 and was payable monthly in arrears.

The minimum Investment Management Fee was borne by the Classes on a pro rata basis by reference to their respective NAVs. The Sub-Investment Manager fee (note 13.4) was settled by the Investment Manager on behalf of the Cell from the proceeds of the Investment Management fee. This minimum excluded the Sub-Investment Management fees and related to the net portion of Investment Management fee of 0.15% only.

Investment Management fee charged during the year and accrued at year end:

	2024	2023
	USD	USD
Charged during the year	11,463	641,076
Accrued at year end	-	49,891

### Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### Notes to the Financial Statements

#### 13. Related party transactions (continued)

#### 13.3 Management, Investment Management and Administration fee

On the 10 July 2023, amendments were made to the Supplemental Cell Prospectus and the following changes became effective from that date:

- A Management agreement was entered into whereby the Manager shall settle the fees of the Administrator and the Investment Manager on behalf of the Cell from the proceeds of the Management fee;
- The Manager will be entitled to the payment of a fee of 0.35% of the NAV of the Cell per annum (subject to a minimum of USD 40,000 per annum) (the "Management Fee"). The Management Fee will accrue as at each Valuation Point, based on the current valuation and is payable monthly in arrears.

Management, Investment Management and Administration fee charged during the year and accrued at year end:

	2024 <u>USD</u>	2023 <u>USD</u>
Charged during the year	192,514	
Accrued at year end	15,555	-

#### 13.4 Sub-Investment Management fee

The Investment Manager has appointed Caleo Capital (Pty) Ltd, a South African registered company, as Sub-Investment Manager (the "Sub-Investment Manager") to the Cell and to any trading subsidiaries of the Cell.

Up until 9 July 2023, the Sub-Investment Manager was entitled to receive a fee of up to 0.85% of the NAV of the Cell attributable to Class A USD Shares per annum (the "Sub-Investment Manager fee"). The Sub-Investment Manager Fee accrued as at each Valuation Point, based on the current valuation, and was payable monthly in arrears. The Investment Manager settled this fee from the proceeds of the Investment Management fee on behalf of the Cell.

On the 10 July 2023, amendments were made to the Supplemental Cell Prospectus and the following changes became effective from the date:

- The fee is based on 0.85% of the NAV of the Cell per annum; and
- The Cell will settle the fee directly

Sub-Investment Management fee charged during the year and accrued at year end:

	2024 <u>USD</u>	2023 <u>USD</u>
Charged during the year	467,535	-
Accrued at year end	37,126	

### Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### Notes to the Financial Statements

#### 13. Related party transactions (continued)

#### 13.5 Custodian fee

Northern Trust (Guernsey) Limited was appointed to provide custodian services. The custodian is entitled to the payment of a fee chargeable on a sliding scale in respect of all Share Classes, as follows, subject to a minimum of USD 8,000 per annum.

Fee% of NAV per annum	<u>Cell NAV</u>
0.05%	Up to USD30 million
0.04%	From USD30 million to USD60 million
0.03%	From USD60 million to USD100 million
0.02%	Over USD100 million

Custodian fee charged during the year and accrued at the year end:

	2024	2023
	USD	USD
Charged during the year	25,608	15,613
Accrued at year end	2,048	4,788

#### **13.6 Distribution Partner fee**

Caleo Capital (Pty) Ltd is appointed as distribution partner to promote and market the Cell. No distribution fee will be payable by the Cell to the Distribution Partner.

#### **13.7 Board of Directors' remuneration**

Up until 9 July 2023, the Directors' fees in respect of the Cell shall not exceed USD 20,000 or currency equivalent in any twelve-month period.

The Directors waived their right to a fee until 9 July 2023. From 10 July 2023, amendments were made to Supplemental Cell Prospectus and effective from that date the Directors will be paid a fee of USD10,000 per annum. In addition, the Directors shall be entitled to be repaid for all reasonable out of pocket expenses properly incurred by them in the performance of their duties to the Cell. Such fees and expenses shall be paid out of the assets of the Cell alone and not from the cellular assets of other cells of the Company or assets of the Company itself.

Directors' fee charged during the year and accrued at the year end:

	2024	2023
	USD	<u>USD</u>
Charged during the year	9,781	-
Accrued at year end	9,781	-

#### 14. Ultimate controlling party

In the opinion of the Directors, on the basis of the shareholdings advised to them, the Cell has no ultimate controlling party.

### Annual Report and Audited Financial Statements for the year ended 30 June 2024

#### Notes to the Financial Statements

#### 15. Reconciliation of published valuation to financial statements

	2024 <u>USD</u>	2023 <u>USD</u>
Net assets attributable to holders of participating redeemable shares		
per financial statements Adjustments:	57,268,915	60,045,807
Adjustment in value of assets at financial assets at fair value through	11 009	(01 007)
profit and loss	11,008	(81,087)
Adjustment in accruals	(1,298)	960
Net assets attributable to holders of participating redeemable shares		
per published valuation	57,278,625	59,965,680
NAV per Class A per published valuation	1.51	1.38
NAV per Class A per financial statements	1.51	1.39

#### **16. Subsequent events**

These financial statements were approved for issuance by the Board on 2 October 2024. Subsequent events have been evaluated until this date.

No significant subsequent events which have occurred in respect of the Cell that are considered material to the understanding of these audited financial statements.